Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 222

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Factor VIIa is not just a factor X activator

Jeremy P. Wood

Blood (2021) 137 (24): 3324–3325.

https://doi.org/10.1182/blood.2021010839

Published: 2021

Journal Articles

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

Georg Obermayer, Taras Afonyushkin, Laura Göderle, Florian Puhm, Waltraud Schrottmaier, Soreen Taqi, Michael Schwameis, Cihan Ay, Ingrid Pabinger, Bernd Jilma, Alice Assinger, Nigel Mackman, Christoph J. Binder

Blood (2021) 137 (10): 1406–1415.

https://doi.org/10.1182/blood.2020007155

Published: 2021

Includes: Supplemental data

Journal Articles

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Ammon Fager, MD PhD, Maureane Hoffman, MD PhD, Dougald Monroe, PhD

Blood (2019) 134 (Supplement_1): 3623.

https://doi.org/10.1182/blood-2019-124428

Published: 2019

Journal Articles

A FULLY Human Bispecific Antibody Functionally Rescues Factor VIII Deficiency EX VIVO

Wei Wang, PhD, John Blackwood, PhD, Roberto Magliozzi, PhD, Leonardo Moraes, PhD, Jeffrey Hollins, PhD, Alessandro Sinopoli, PhD, Bertie Chi, PhD, Laura Mitchell, PhD, Chris Sellick, PhD, Claire Pearce, PhD, Igor Theurl, MD PhD, Volker Germaschewski, Jacob Galson, PhD, Luca Badiali, PhD, Karen Dickson, PhD, Allan Bradley, PhD, E-Chiang Lee, PhD

Blood (2019) 134 (Supplement_1): 2410.

https://doi.org/10.1182/blood-2019-123359

Published: 2019

Journal Articles

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Shiva Keshava Gaddam Bala Krishna, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 1136.

https://doi.org/10.1182/blood-2019-128474

Published: 2019

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Journal Articles

Clinical, Laboratory and Molecular Characterization of Factor VII, Factor X and Their Combined Deficiencies in a Tertiary Care Center

Bereczky Zsuzsanna, MD PhD, Speker Marianna, Al-Muhanna Marie, Balogh Gábor, Boda Zoltán, MD PhD DSc, Pfliegler György, MD PhD, Schlammadinger Ágota, MD PhD, Kerényi Adrienn, MD PhD, Csongor Kiss, MD PhD DSc

Blood (2019) 134 (Supplement_1): 2394.

https://doi.org/10.1182/blood-2019-125504

Published: 2019

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition

Viviane S. De Paula, Nikolaos G. Sgourakis, Ivo M. B. Francischetti, Fabio C. L. Almeida, Robson Q. Monteiro, Ana Paula Valente

Blood (2019) 134 (8): 699–708.

https://doi.org/10.1182/blood.2018889493

Published: 2019

Includes: Supplemental data

Journal Articles

A Novel Variant of Factor VIII Yields Cofactor Activity without Proteolysis between the A1 and A2 Domains

Manjunath Goolyam Basavaraj, PhD, Sriram Krishnaswamy, PhD

Blood (2018) 132 (Supplement 1): 3771.

https://doi.org/10.1182/blood-2018-99-116267

Published: 2018

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

Dougald Monroe, PhD, Maureane Hoffman, MD

Blood (2018) 132 (Supplement 1): 1167.

https://doi.org/10.1182/blood-2018-99-116888

Published: 2018

Journal Articles

On-Demand Treatment of Bleeding Episodes in Patients with Hereditary Factor X Deficiency Using a High-Purity Factor X Concentrate: Data from 2 Clinical Trials and a Data-Collection Study

James N. Huang, MD, Chioma Akanezi, BSc, PgDip, Amy Shapiro

Blood (2018) 132 (Supplement 1): 1215.

https://doi.org/10.1182/blood-2018-99-111397

Published: 2018

Journal Articles

The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants

Elisabeth Andersen, MSc, Maria Eugenia Chollet, Marcello Baroni, Mirko Pinotti, Francesco Bernardi, Ellen Skarpen, Per Morten Sandset, Grethe Skretting

Blood (2018) 132 (Supplement 1): 3777.

https://doi.org/10.1182/blood-2018-99-118246

Published: 2018

Journal Articles

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

Gina Patel, Parameswaran Hari, MD MRCP, MS, Aniko Szabo, PhD, Rein Lisa, Lisa M. Baumann Kreuziger, MD MS, Saurabh Chhabra, MD, Binod Dhakal, MBBS, Anita D'Souza, MBBS

Blood (2017) 130 (Supplement 1): 2363.

https://doi.org/10.1182/blood.V130.Suppl_1.2363.2363

Published: 2017

Journal Articles

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Terrence J Bradley, MD, Matthew P Salzberg, MD, George Nahas, DO, Basem Azab, MD, Alan Livingstone, MD, John J. Byrnes, MD, Thomas J. Harrington, MD, James E. Hoffman, MD

Blood (2017) 130 (Supplement 1): 4885.

https://doi.org/10.1182/blood.V130.Suppl_1.4885.4885

Published: 2017

Journal Articles

Acquired Factor X Deficiency in Systemic Light Chain Amyloidosis: Factor X Recovery after Bleeding Complications, Splenectomy, Chemotherapy and Remission

Rosa Toenges, MD, Juliane Steinmann, MD, Annelie Siegemund, MD, Hubert Serve, Wolfgang A. Miesbach, MD PhD

Blood (2017) 130 (Supplement 1): 4892.

https://doi.org/10.1182/blood.V130.Suppl_1.4892.4892

Published: 2017

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Factor VIIa is not just a factor X activator

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

A FULLY Human Bispecific Antibody Functionally Rescues Factor VIII Deficiency EX VIVO

Therapeutic Doses of Recombinant FVIIa in Hemophilia Generates Thrombin in Platelet-Dependent and -Independent Manner

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Clinical, Laboratory and Molecular Characterization of Factor VII, Factor X and Their Combined Deficiencies in a Tertiary Care Center

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition

A Novel Variant of Factor VIII Yields Cofactor Activity without Proteolysis between the A1 and A2 Domains

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

On-Demand Treatment of Bleeding Episodes in Patients with Hereditary Factor X Deficiency Using a High-Purity Factor X Concentrate: Data from 2 Clinical Trials and a Data-Collection Study

The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants

Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Acquired Factor X Deficiency in Systemic Light Chain Amyloidosis: Factor X Recovery after Bleeding Complications, Splenectomy, Chemotherapy and Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only